Introduction Phenylalanine hydroxylase (PAH) requires the reduced pterin cofactor (6R)-T.-erythro-5,6,7,8-tetrahydrobiopterin (6R-BH4) to reduce the iron [(Fe(II1)--->Fe(II)
] at the active site, to activate dioxygen and hydroxylate the aromatic ring of the amino acid substrate L-phenylalanine (L-Phe). In addition, it also functions as a potent negative effector of the activation of the enzyme by L-Phe and the phosphorylation of Serl6 by cyclic AMP-dependent protein kinase (PKA) [1, 2] . The rate of PKAdependent phosphorylation is inhibited only by pterin co factors [(6R-BH4)' (6S-BH4) og 7,8-dihydro-Lbiopterin (BH 2 )] that are able to decrease the potency and efficiency of L-Phe as an activator of the hydroxylase [2] . These fmdings have been interpreted in terms of an interdomain conformational change induced by the pterin binding at the active site [2] . The recent X-ray crystal structures of three different truncated forms of the enzyme have yielded valuable new information on its structure and function [3] , including a structural explanation for the inhibitory effects of the pterin cofactors as affered in the present study.
Materials and Methods

Expression in E. coli and purification of recombinant hPAH forms
Wild-type and mutant forms of the double truncated dimeric form deltaNI02/deItaCi4-hPAH were expressed as fusion proteins in E. coli, using the maltose-binding protein (MBP) as fusion partner, purified by affinity chromatography (as fusion protein) and size exclusion chromatography (after cleavage with the restriction protease factor Xa) [4] . The PAH activity was determined as described [5] .
Si:e-specific mutagenesis
Mutations were introduced into the double truncated form of the wt-hPAH cDNA (deItaNI02/deItaC24-hP AH) by PCR-based site-specific mutagenesis as described [4, 6] .
Crystallization, data collection, model building and refinement
The wild-type form of the double truncated form of hPAH (deltaN102/deltaC24-hPAH) was cocrystallized with the oxidized form of the natural cofactor 7,8-dihydro-L-biopterin (BH 2 ) [6] with a similar size and morphology as the original native crystals [7] . Data collection, model building and refinement were carried out as described [6, 7] .
Results and Discussion
Pterin binding at the active site of hP A H
The crystal structure (at 2.0 A resolution) of the binary complex of dirneric catalytic domain (residues 118-424) of human PAH (hPAH) [6] could be superimposed on the crystal structure of the corresponding ligand-free native form [7] with a rootmean-square displacement of 0.26 A. Electron density difference maps showed density that could be interpreted as the pterin ring, and allowed for the positioning of the ring as well as the 04 oxygen atom ard the dihydroxypropyl side-chain [6) . The pterin binds lD the second coordination sphere of the catalync Iron (the C4a atom is 6.1 A away), and interacts through several hydrogen bonds to two water molecules coordinated to the iron, as well as to the main chain carbonyl oxygens of A322, G247 and L249 and the main chain amide of L249 (see Table 1 for atomic distances). The pterin ring forms an aromatic pi-stacking interaction with F254, and Y325 also contributes to the positioning of the pterin ring and its dihydroxypropyl side-chain by hydrophobic interactions. E286 hydrogen bonds to one of the water molecules coordinated to the iron as well as to a water molecule which hydrogen bonds to N3 of the pterin ring. 
Conformational changes in the protein and the cofactor on ligand binding
Some important conformational changes are seen in the active site upon pterin binding, including movements of the 245-250 loop and the 380's loop in the direction of the iron and thus allows for several important H-bonds to the pterin to be formed [6] . These are rather flexible loops as indicated by a high B-factor. Thus, the C aJpha atom of G247 moves about 1.3 A towards the pterin ring, when compared to the native ligand-free structure. L248 side-chain changes its conformation as compared to the non-liganded structure, and now faces the active site. L255 also shifts its conformation in order to accomodate the dihydroxypropyl side-chain of the pterin. Mutations in G247 (G247V), L249 (L249FIH) and L255 (L255V/S) have been reported m patients with phenylketonuria (PKU database located at http://www.mcgill.ca/pahdb).
Considering the important hydrogen bonds between the cofactor and these active site residues as well as the movements G247 undergo upon pterin binding, the dysfunction of the mutant enzyme forms can be easily understood.
Recent NMR studies have shown a change in the conformation of the side-chain of BH2 from a trans in solution to an almost cis in the bound state [8] , which was also observed in the crystal structure with a torsional angle between the OH groups of about 53° [6] . The pterin cofactor is in an ideal orientation and conformation for dioxygen to bind in a bridging position between iron and the pterin.
In 1984 we proposed [1] a working model with four alternative conformations of rat P AH: the resting or ground state (G-state), the L-Phe activated state (Pstate), the 6R-BR 4 inhibited state (B-state) and a state of catalytic turnover (BP-state). We have now structural evidence for conformational changes at the active site on pterin binding (see above) . That additional conformational changes do occur on pterin binding to the full-length tetrameric enzyme is suggested by the i.nhib itor;.: effect of 6R-BH, on both limited proteolysis, activation by L-Phe and phosphory )ation of Serl6 in rat PAH by PKA (apparent K, = 1.9 !lM) [ 1 ,2] . The same effects have been observed for hP AH, with a similar inhibitor constant for 6R-BH 4 as in rat PAH [Solstad T and Flatmark T, unpublished data] . Furthermore, superposition of the binary hPAH-BH2 complex onto the crystal structure of the ligand-free dimeric rat P AH [9] , which contains both the regulatory and catalytic domains, reveals that the C2'-0R group of BH2 is sufficiently close (2.7 A) to form hydrogen bonds to Ser23 (Figure 1 ) through either the sidechain or the carbonyl oxygen of the main chain. Thus, upon 6R-BH/BH 2 binding to the full -length P AH, a conformational change of the protein including a movement of the mobile N-tenninal autoregula tory sequence [9] is likely to occur, forming the proper length hydrogen bonds to the pterin. These interactions gives a plausible structural explanation for the specific regulatory properties of the dihydrox)'J-ropyl side-chain of BH4 (negative effector) in the full-l ength enzyme in terms of phosphorylation of Serl6 by PKA and activation by L-Phe [1, 2] . Similar mteractions with the N-terminal autoregulato.ry sequence was observed for ironcoordinated catecholamine also explaining the inhibitory effect of dopamine binding on the rate of phosphorylatiGn of Ser16 in full-length hPAH by PKA [Solstad T and Flatmark T, unpublished data). Thus, in order to explain the regulatory properties of 6R-BH 4 in the full-length form of PAH it is not necessary to have .. 0 additional binding site of the cofactor in the rebulatory domain as recently postulated [9] .
